E.1 Weight management

Overview of the PICO structure

Definition of the i	intervention
Weight managem care or communit adults who are ov underweight or m The evidence synt	ent refers to nonsurgical interventions adopting unimodal or multimodal interventions that can be delivered in a primary y setting and are aimed at improving outcomes for adults with CPLBP. These interventions may include weight loss for rerweight or obese, weight maintenance for adults of normal body weight or weight gain interventions for adults who are nalnourished. thesis for the guideline identified trials of weight loss interventions only.
PICO question	
Population and subgroups	 Community-dwelling adults (aged 20 years and over) experiencing chronic primary low back pain, with or without leg pain, including older people (aged 60 years and older). Subgroups: Age (all adults and those aged 60 years and over) Gender and/or sex Presence of leg pain (radicular, non-radicular, mixed) Race/ethnicity - studies of populations who were historically marginalized compared with studies of those who were not Regional economic development - studies carried out in high-income countries compared with studies in low- to middle-income countries
Comparators	 a) Placebo/sham b) No or minimal intervention, or where the effect of the intervention can be isolated c) Usual care (described as usual care in the trial)

Outcomes	Critical outcomes constructs (all adults) Critical outcomes constructs (older adults, aged ≥ 60 years) Pain Back-specific function/disability General function/disability General function/disability Health-related quality of life Psychosocial function Social participation Social participation Self-efficacy Adverse events (as reported in trials) Body weight Pain Back-specific function/disability General function/disability General function/disability Body weight Pain Back-specific function/disability General function/disability General function/disability General function/disability General function Adverse events (as reported in trials) Change in the use of medications Falls Body weight
1	

Other Evidence-to-Decision (EtD) considerations for pharmacological and non-pharmacological weight loss interventions

Summary of values and preferences							
All adults	Older people						
No evidence synthesis commissioned for all adults. Judgements made based on experience of GDG members	No evidence identified						

Summary of resource considerations							
All adults	Older people						
No evidence synthesis commissioned for all adults. Judgements made based on experience of GDG members	No evidence identified						

Summary of equity and human rights considerations							
All adults	Older people						
No evidence synthesis commissioned for all adults. Judgements made based on experience of GDG members	No evidence identified						

Summary of acceptability considerations							
All adults	Older people						
No evidence synthesis commissioned for all adults. Judgements made based on experience of GDG members	No evidence identified						

Summary of feasibility considerations						
All adults	Older people					
No evidence synthesis commissioned for all adults. Judgements made based on experience of GDG members	No evidence identified					

E.1.1 Summary of judgements: pharmacological weight loss

Domain	All adults	Older people
Benefits	Uncertain	Uncertain

Harms	Uncertain	Uncertain
Balance benefits to harms	Uncertain; probably does not favour pharmacological weight loss	Uncertain; probably does not favour pharmacological weight loss
Overall certainty	Very low	Very low
Values and preferences	Probably important uncertainty or variability	Probably important uncertainty or variability
Resource considerations	Moderate costs; varies (according to country and health system)	Moderate costs; varies (according to country and health system)
Equity and human rights	Possibly increased; uncertain; possibly reduced (especially related to stigma)	Possibly increased; uncertain; possibly reduced (especially related to stigma)
Acceptability	Yes, probably yes (among health workers); uncertain for people with CPLBP	Yes, probably yes (among health workers); uncertain for people with CPLBP
Feasibility	Probably yes, probably no, uncertain, varies	Probably yes, probably no, uncertain, varies

E.1.2 Summary of judgements: non-pharmacological weight loss

Domain	All adults	Older people
Benefits	Uncertain	Uncertain
Harms	Uncertain	Uncertain
Balance benefits to harms	Uncertain	Uncertain
Overall certainty	Very low	Very low
Values and preferences	Probably important uncertainty or variability	Probably important uncertainty or variability
Resource considerations	Moderate costs; varies (according to country and health system)	Moderate costs; varies (according to country and health system)

Equity and human rights	Possibly increased; uncertain; possibly reduced (especially related to stigma)	Possibly increased; uncertain; possibly reduced (especially related to stigma)
Acceptability	Yes, probably yes (among health workers); uncertain for people with CPLBP	Yes, probably yes (among health workers); uncertain for people with CPLBP
Feasibility	Probably yes, probably no, uncertain, varies	Probably yes, probably no, uncertain, varies

<u>GRADE Table 1</u>. What are the benefits and harms of pharmacological weight loss interventions for adults with chronic primary low back pain compared with <u>placebo</u>?

Population: People with lower back pain Setting: Varied Intervention: Weight loss interventions Comparator: Placebo												
Certainty Assessment				Number of participants		Effect:	Certainty	Comment				
Outcomes	No. studi es	Study Design	Risk of bias	Inconsistenc y	Indirectnes s	Imprecisio n	Other	Weight loss	Placebo	Absolute (95%Cl)		
Pain intensity – post-intervent	ion											
Pharmacological weight loss intervention vs placebo assessed with: McGill Pain Questionnaire Follow-up: mean 10 weeks	1ª	RCT	Very serious ^b	Serious	Serious ^d	Serious	-	48	48	MD -11.4 [-16.68 to - 6.12]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 2.1
Population subgroup 1 by inte	rvention	- not repo	rted (no subg	group analysis wa	is performed; o	nly one include	d study for	this outcome)	1	:	•	
Population subgroup 2 by 60 y	ears and	d over - no	t reported (n	o subgroup analy	sis was perforn	ned; only one ir	cluded stu	dy for this outcor	ne)			
Population subgroup 3 by gen	der/sex ·	- not repor	ted (no subg	roup analysis was	s performed; on	ly one included	study for th	nis outcome)				
Population subgroup 4 by pres	sence of	leg pain o	r radicular s	ymptoms (no sul	ogroup analysis	was performed	l; only one	included study fo	or this outcome)			
Population subgroup 5 by race	e/ethnici	ty (no subg	roup analysis	was performed;	only one includ	ed study for this	s outcome)					
Population subgroup 6 by regional economic development (no subgroup analysis was performed; only one included study for this outcome)												
Pain intensity – long-term follow-up												
-	-	-	-	-	-	-	-	-	-	-	-	-

Self-reported activity limitation	ı (Disabi	lity/Functio	on) – post-in	tervention								
Pharmacological weight loss intervention vs placebo assessed with: Oswestry LBP Questionnaire Follow-up: mean 10 weeks	1a	RCT	Very serious ^b	Serious	Serious ^d	Serious ^e	-	48	48	MD -4.9 [-19.45 to 9.65]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 2.2
Population subgroups 1, 2, 3, 4	4 , 5 and	6 - not rep	orted (no su	bgroup analysis v	vas performed)	<u>I</u>	1	1		1	·!	
Self-reported activity limitation	ı (Disabi	lity/Function	on) – long-te	rm follow-up: no	studies were	identified that	reported f	or this outcome				
-	-	-	-	-	-	-	-	-	-	-	-	-
Health related quality of life – p	oost-inte	rvention:	1							'		
Pharmacological weight loss intervention vs placebo assessed with: Physical subscale of Short Form-36 Follow-up: 10 weeks	1ª	RCT	Very serious ^b	Not serious	Serious ^d	Serious	-	48	48	MD -8.00 [5.07 to 10.93]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 2.3
Pharmacological weight loss interventions vs placebo assessed with: Psychological subscale of Short Form-36 Follow-up: 10 weeks	1a	RCT	Very serious ^b	Not serious	Serious ^d	Serious	-	48	48	MD 5.4 [3.14 to 7.66]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 2.4
	-	-	-	-	-	-	-	-	-	-	-	-
Health related quality of life – I	ong-tern	n follow-up	: no studies	were identified	that reported f	or this outcon	ne					
•	-	-	-	-	-	-	-	-	-	-	-	-
Weight – post-intervention			1							'		
Pharmacological weight loss interventions vs placebo assessed with: Weight (kg) Follow-up: range 10 weeks to 12 weeks	2a,f	RCT	Very serious ^g	Serious ^h	Not serious	Serious ⁱ	-	105	103	MD -1.61 [-8.53 to 5.31]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 2.5

Population subgroups 1, 2, 3, 4	, 5 and 6	6 - not repo	orted (no sub	ogroup analysis wa	as performed)							
Weight/BMI – long-term follow-	up: no s	tudies wer	e identified	that reported for	this outcome							
-	-	-	-	-	-	-	-	-	-	-	-	-
Psychological functioning and	wellbein	ıg – post-iı	ntervention	or long-term follo	ow-up: no stud	lies were iden	tified that r	eported for this	outcome			
-	-	-	-	-	-	-	-	-	-	-	-	-
Social participation – post-inte	rvention	or long-te	rm follow-u	o: no studies we	re identified th	at reported fo	r this outco	ome				
-	-	-	-	-	-	-	-	-	-	-	-	-
Self-efficacy – post-interventio	n or long	g-term follo	ow-up: no st	udies were ident	ified that repo	rted for this o	utcome					
-	-	-	-	-	-	-	-	-	-	-	-	-
Change in use of medications -	- post-in	tervention	or long-terr	n follow-up: no s	studies were id	lentified that r	eported for	this outcome				
	-	-	-	-	-	-	-	-	-	-	-	-
Falls – post-intervention or lon	g-term fo	ollow-up: r	no studies w	ere identified that	at reported for	this outcome						
-	-	-	-	-	-	-	-	-	-	-	-	-
Adverse events – post-interver	ition:											
Pharmacological weight loss interventions vs placebo, assessed with: Frequency (n/ N, %.)	2 ^{a,f}	RCT	Very serious ^g	Not serious	Not serious	Serious ^e	-	41/105 (40.35%)	28/103 (32.7%),	RR 1.41 [0.95 to 2.10]		Appendix 5 Analysis 2.6
Follow-up: 10 to 12 weeks											very low	
Population subgroups 1, 2, 3, 4	, 5 and 6	6 - not repo	orted (no sub	ogroup analysis wa	as performed)							
Adverse events – long-term fol	low-up:	no studies	were identi	fied that reported	d for this outco	ome						

_	_	_	_	_		_	_	_	_	_	_	_
-	-	-	-	-	-	-	-	-	-	-	-	-

Explanation

- a. Muehlbacher, 2006 10-weeks topiramate drug compared to placebo (blinded).
- b. Risk of Bias: Downgrade two levels overall high risk of bias in single study
- c. Inconsistency: Downgrade one level for unexplained variability in result (SD reported likely to be SE) and unable to contact authors to confirm.
- d. Indirectness: Single study
- e. Imprecision: Downgraded one level for small sample size
- f. Kwon, 2021- 12-weeks orlistat plus phentermine drugs compared to phentermine plus placebo.
 g. Risk of Bias: Downgrade two level overall high risk of bias in all studies
- h. Inconsistency: Downgrade one level due to substantial heterogeneity (I2=74%)
- i. Imprecision: Downgrade one levels CIs show appreciable benefit and harm; not downgraded two levels due to downgrade for inconsistency would have contributed to severity of imprecision.

<u>GRADE Table 2</u>. What are the benefits and harms of non-pharmacological weight loss interventions for adults with chronic primary low back pain compared with <u>minimal</u> or <u>no intervention</u>?

Population: People with lower b Setting: Varied Intervention: Weight loss interve Comparator: No or minimal care	ack pain entions											
		Ce	ertainty Asse	ssment				Number of	participants	Effect:	Certainty	Comment
Outcomes	No. studi es	Study Design	Risk of bias	Inconsistenc y	Indirectnes s	Imprecisio n	Other	Weight loss	No or minimal intervention	(95%CI)		
Pain – post-intervention												
Diet (A) or Diet and extra virgin olive oil (B) vs olive oil only (C) assessed with: Presence of severe pain n/% Follow-up: mean 12 weeks	1ª	RCT	Very serious ^ь	Not serious	Serious⁰	Very serious ^d	-	90	43	RR 0.94 [0.68 to 1.28]	⊕⊖⊖ ⊖ Very low	Effect estimate calculated by pooling A+B vs C Appendix 5 Analysis 3.1
Population subgroups 1, 2, 3, 4	4, 5 and (6 - not repo	orted (no sub	ogroup analysis w	as performed; o	only one include	ed study for	this outcome)			1	
Pain- long-term follow-up												
-	-	-	-	-	-	-	-	-	-	-	-	-
Self-reported activity limitation	(Disabil	lity/Functio	on) – post-in	tervention or lor	ng-term follow-	up: no studies	s were ider	ntified that repo	rted for this out	come		
-	-	-	-	-	-	-	-	-	-	-	-	-
Health related quality of life – p	oost-inte	rvention o	r long-term	follow-up: no stu	ıdies were idei	ntified that rep	orted for t	his outcome				
-	-	-	-	-	-	-	-	-	-	-	-	-
Weight and BMI – post-interver	ntion				·			·		·		·

											1	
Diet (intv A) or Diet and extra virgin olive oil (intv B) vs olive oil only (control) assessed with: BMI change follow-up: 12 weeks	1a	RCT	Very serious ^b	not serious	Serious⁰	Serious ^e	-	A: 43 B:47	43	A: -2.65 ± 5.54 kg/m2 B: -1.64 ± 3.47 kg/m2 C: $+1.66\pm2.94$ kg/m2	⊕⊖⊖ ⊖ Very low	Estimate from single study, data otherwise not usable.
Aerobic exercise and diet (A) vs no intervention control (B) Assessed with: Weight change from baseline (kg) Follow-up: 4 months	1 f	RCT	Very serious⁵	not serious	Serious⁰	Very serious ^e	-	18	18	A: - 4.3 kg B: -1.4 kg [p=0.0001]	⊕⊖⊖ ⊖ Very low	Estimate from single study, data otherwise not usable.
Population subgroup 1 - not re	ported (no subgrou	p analysis wa	as performed; sing	gle study result	provided above	e as meta-a	nalysis not possi	ble due to insuf	icient data)		
Population subgroup analysis	2 by 60 y	years and	over									
Aerobic exercise and diet (A) vs no intervention control (B) Assessed with: Weight change from baseline (kg) Follow-up: 4 months Mean age: 63 years (SD2.4)	1f	RCT	Very serious ^b	not serious	Serious⁰	Very serious ^g	-	18	18	A: - 4.3 kg B: -1.4 kg [p=0.0001]	⊕⊖⊖ ⊖ Very low	Estimate from single study, data otherwise not usable.
Population subgroup analysis	3 by ger	nder/sex	-		-							
Aerobic exercise and diet (A) vs no intervention control (B) Assessed with: Weight change from baseline (kg) Follow-up: 4 months Gender: Males	1f	RCT	Very serious ^b	not serious	Serious⁰	Serious ^g	-	18	18	A: - 4.3 kg B: -1.4 kg [p=0.0001]	⊕⊖⊖ ⊖ Very low	Estimate from single study, data otherwise not usable.
Population subgroups 4, 5 and	6 - not i	reported (n	io subgroup a	inalysis was perfo	ormed)							
Weight/BMI – long-term follow-	up: no s	tudies we	re identified	that reported for	this outcome							
-	-	-	-	-	-	-	-	-	-	-	-	-
Psychological functioning and	wellbeir	ng – post-i	ntervention	or long-term foll	ow-up : no stu	dies were iden	tified that	reported for this	s outcome			
-	-	-	-	-	-	-	-	-	-	-	-	-

Social participation – post-inte	rvention	or long-te	erm follow-u	p: no studies we	re identified th	nat reported for	r this outco	ome					
-	-	-	-	-	-	-	-	-	-	-	-	-	
Self-efficacy – post-interventio	n or lon	g-term follo	ow-up: no st	udies were iden	tified that repo	orted for this o	utcome						
-	-	-	-	-	-	-	-	-	-	-	-	-	
Change in use of medications – post-intervention or long-term follow-up: no studies were identified that reported for this outcome													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Falls – post-intervention or lon	g-term f	ollow-up: r	no studies w	vere identified the	at reported for	this outcome							
-	-	-	-	-	-	-	-	-	-	-	-	-	
Adverse events – post-interver	ntion or I	ong-term f	follow-up: n	o studies were ic	lentified that r	eported for this	s outcome						
-	-	-	-	-	_	-	-	-	-	-	-	-	

Explanation

- a. Mendonca 2021- 12 weeks individualised meal plan (5-10% energy deficit) with or without 52mls/day of olive oil compared to 52mls of daily olive oil.
 b. Risk of Bias: Downgrade two levels for overall high risk of bias in single study
- Indirectness: Single Study C.
- Imprecision: Downgraded two levels as CIs show appreciable benefit and harm and small numbers of participants
 Imprecision: Downgraded one level for small sample size
- Irondoust 2021- 30 days; simple dietitian prescribed 30-day weight loss meal plan containing less than 1200kcal per day. Telephone call and text message follow-up every 3 days to monitor adherence, plus NSAID celecoxib 200mg/day. f.
- g. Imprecision: Downgraded two levels for very small sample size.

<u>GRADE Table 3</u>. What are the benefits and harms of non-pharmacological weight loss interventions for adults with chronic primary low back pain compared with <u>usual care</u>?

Population: People with lower based setting: varied secondary care Intervention: Weight loss interver Comparator: Usual care	ack pain entions											
		Ce	rtainty Asse	ssment				Number of	participants	Effect:	Certainty	Comment
Outcomes	No. studi es	Study Design	Risk of bias	Inconsistenc y	Indirectnes s	Imprecisio n	Other	Weight loss	Usual Care	Absolute (95%Cl)		
Pain intensity – post-interventi	on											
Weight loss interventions vs usual care assessed with: MPQ, VAS, NRS Follow-up: range 60 days to 26 weeks.	4a,b,c	RCT	Serious ^d	Very serious ^e	not serious	Serious ^f	-	167	148	SMD 0.18 [-0.46, 0.81]	⊕⊖⊖⊖ Very low	Appendix 5 Analysis 1.1
Population subgroup analysis	1 by inte	ervention t	уре									
Diet only weight loss vs usual care assessed with: MPQ, VAS Follow-up: range 60 days to 5 weeks	3a,b	RCT	Very serious ^g	Very serious ^e	Not serious	Serious ^f	-	88	68	SMD 0.39 [-0.74, 1.52]	⊕⊖⊖⊖ Very low	Appendix 5 Analysis 1.2
Education and weight loss coaching (diet and exercise) vs usual care assessed with NRS Follow-up: 26 weeks	1¢	RCT	Not serious	Not serious	Serious ^h	Very serious ⁱ	-	79	80	SMD -0.19 [-0.51, 0.12]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.2
Population subgroups 2 and 3	- not rep	oorted (no s	subgroup ana	alysis was perform	ned)	·		·		·	· · · · · · · · · · · · · · · · · · ·	
Population subgroup analysis	4 by pre	sence of le	eg pain or ra	dicular symptom	ıs							

Weight loss interventions in patients with leg pain vs usual care assessed with: MPQ, follow-up: 60 days	1ª	RCT	Very serious ^g	Not serious	Not serious	Serious ^j	-	48	48	SMD -0.57 [-0.97to -0.16]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.3
Weight loss interventions in patients leg pain not reported vs usual care assessed with: VAS, NPS Follow-up: 5 weeks to 26 weeks	3 ^{b,c}	RCT	Serious ^d	Very serious ^e	Not serious	Serious ^f	-	119	100	SMD 0.49 [-0.38 to 1.37]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.3
Population subgroup 5 - not re	ported (no subgrou	p analysis wa	as performed)								
Population subgroup analysis	6 by reg	ional econ	omic develo	pment								
Low-/middle-income countries: Diet only weight loss vs usual care assessed with: MPQ, VAS Follow-up: range 60 days to 5 weeks	3a,b	RCT	Very serious ^g	Very serious ^e	Not serious	Serious ^f	-	88	68	SMD 0.39 [-0.74, 1.52]	⊕⊖⊖⊖ Very low	Appendix 5 Analysis 1.4
High income country: Education and weight loss coaching (diet and exercise) vs usual care assessed with NRS Follow-up: 26 weeks	1¢	RCT	Not serious	Not serious	Serious ^h	Very serious ⁱ	-	79	80	SMD -0.19 [-0.51, 0.12]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.4
Pain intensity – long-term follo	w-up											
-	-	-	-	-	-	-	-	-	-	-	-	-
Self-reported activity limitation	(Disabi	lity/Function	on) – post-in	tervention		·				·	·	
Weight loss interventions vs usual care assessed with: RMDQ, Barthel Index Follow-up: range 60 days to 26 weeks	4a,b,c	RCT	Very serious ^g	Serious ^k	Not serious	Serious ⁱ	-	126	123	SMD -0.65 [-1.12 to -0.19]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.5

Population subgroup analysis	1 by inte	rvention t	уре									
Diet only weight loss interventions vs usual care assessed with: RMDQ, Barthel Index Follow-up: range 60 days to 5 weeks	3a,b	RCT	very serious ^g	Not serious	Not serious	Serious ^j	-	88	68	SMD -0.88 [-1.22 to -0.54]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.6
Education and weight loss coaching (diet and exercise) vs usual care assessed with RMDQ Follow-up: 26 weeks	1¢	RCT	Serious ^ı	Serious ^h	Not serious	Very serious ⁱ	-	38	55	SMD -0.13 [-0.54, 0.28]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.6
Population subgroups 2 and 3	- not rep	orted (no s	subgroup ana	lysis was perform	ned)							
Population subgroup analysis	4 by pre	sence of le	eg pain or ra	dicular sympton	ns							
Diet only weight loss interventions vs usual care assessed with: RMDQ Follow-up: 60 days	1 ^a	RCT	Serious ^g	not serious	Serious ^h	Serious ⁱ	-	48	48	SMD-0.86, [-1.28 to -0.44]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.7
Diet, or weight loss coaching (diet and exercise) vs usual care assessed with: RMDQ, Barthel Index Follow-up: 5 weeks to 26 weeks	3 ^{b,c}	RCT	Serious ^d	Serious ^k	not serious	Seriousi	-	78	75	SMD -0.57 [-1.18 to 0.04]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.7
Population subgroup 5 - not re	ported (no subgrou	p analysis wa	as performed)	•		•	•		•	• • • • •	
Population subgroup analysis	6 by reg	ional econ	omic develo	pment								
Low-/middle-income countries: Diet only weight loss interventions vs usual care assessed with: RMDQ, Barthel Index Follow-up: range 60 days to 5 weeks	2 ^{a,b}	RCT	Very serious ^g	Not serious	Not serious	Serious ⁱ	_	88	68	SMD -0.88 [-1.22 to -0.54]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.8

High income country: Education and weight loss	1¢	RCT	Serious ^ı	Not serious	Serious ^h	Very serious ⁱ	-	38	55	SMD -0.13 [-0.54, 0.28]	⊕00	Appendix 5
coaching (diet and exercise) vs usual care assessed with RMDQ Follow-up: 26 weeks											Very low	Analysis 1.8
Self-reported activity limitation	(Disabil	ity/Functio	on) – long-te	rm follow-up: no	studies were	identified that	reported fo	or this outcome				
-	-	-	-	-	-	-	-	-	-	-	-	-
Health related quality of life – p	ost-inte	rvention										
Education and weight loss coaching (diet and exercise) vs usual care	1°	RCT	Serious ^ı	Not serious	Serious ^h	Very serious ⁱ	-	43	61	MD (PCS) 1.6 [-2.53 to 5.73]	⊕OO ○	Appendix 5
assessed with: SF12-v2 Physical function subscale score (PCS) and Mental subscale score (MCS) follow-up: mean 26 weeks										MD (MCS) 2.20 [-3.11 to 7.51]	Very low	Analysis 1.9 and 1.10
Population subgroups 1, 2, 3, 4	, 5 and 6	6 - not repo	orted (no sub	group analysis w	as performed; o	nly one include	d study for	this outcome)				
Health related quality of life – lo	ong-term	n follow-up	: no studies	were identified	that reported f	or this outcom	ie					
-	-	-	-	-	-	-	-	-	-	-	-	-
Weight and BMI – post-interver	ition											
Weight loss interventions vs usual care assessed with: Weight (kg) follow-up: range 30 days to 26 weeks	4a,b,c	RCT	Very serious ^g	Not serious	Not serious	Very serious ⁱ	-	142	131	MD 0.84 [-2.29 to 3.98]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.11
Weight loss interventions vs usual care assessed with: BMI (kg/m²) follow-up: range 5 weeks to 26 weeks	3 b,c	RCT	Serious ^d	Not serious	Not serious	Very serious ⁱ	-	94	83	MD 0.71 [-0.54 to 1.96]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.15

Population subgroup analysis	1 by inte	ervention t	уре									
Diet only weight loss	3a,b	RCT	Very	Not serious	Not serious	Very	-	88	68	MD 1.06	⊕00	Appendix 5
assessed with: Weight (kg)			serious			serious				[-2.57 to 4.69]	\bigcirc	Analysis 1.12
follow-up: range 30 days to 5 weeks											Very low	
Education and weight loss	1°	RCT	Serious ⁱ	Not serious	Serious ^h	Serious ^j	-	54	63	MD 0.6		Appendix 5
usual care										[0.0 to 1.2]	0	Analysis 1.12
assessed with: Weight (kg) follow-up: 26 weeks											Very low	
Weight loss interventions vs	2 ^b	RCT	Very	not serious	Serious ^h	Very	-	40	20	MD 1.48		Appendix 5
assessed with: BMI (kg/m ²)			36110039			Sellous				[-0.31 to 3.40]	0	Analysis 1.16
follow-up: range 5 weeks											Very low	
Weight loss interventions vs	1¢	RCT	Serious ^ı	Not serious	Serious ^h	Very	-	54	63	MD 0.20	⊕∩∩	Appendix 5
usual care						serious ⁱ				[-1.41 to 1.81]		Analysis 1 16
follow-up: 26 weeks											Very low	
Population subgroups 2 and 3	- not rep	oorted (no s	subgroup ana	lysis was perforn	ned)							
Population subgroup analysis	4 by pre	sence of le	eg pain or ra	dicular sympton	ns							
Diet only weight loss	1ª	RCT	Serious ^g	not serious	Serious ^h	Very	-	48	48	SMD 0.39	⊕00	Appendix 5
assessed with: Weight (kg)						3611003				[-4.47 10 0.20	0	Analysis 1.13
Tollow-up: 30 days											Very low	
Diet, or weight loss coaching	3b,c	RCT	Seriousd	Not serious	Not serious	Very	-	94	83	SMD 1.17	⊕00	Appendix 5
(diet and exercise) vs usual care						serious				[-2.94 to 5.27]	0	Analysis 1.13
assessed with: Weight (kg) follow-up: 5 weeks to 26 weeks											Very low	

Not possible to perform for BMI												
Population subgroup 5 - not re	ported (r	no subgrou	p analysis wa	is performed)								
Population subgroup analysis	6 by reg	ional econ	omic develo	pment								
Low-/middle-income countries: Diet only weight loss interventions vs usual care assessed with: Weight (kg) Barthel Index follow-up: range 30 days to 5 weeks	3a,b	RCT	Very serious ^g	Not serious	Not serious	Very serious ⁱ	-	88	68	MD 1.06, [-2.57, 4.69]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.14
High income country: Education and weight loss coaching (diet and exercise) vs usual care assessed with: Weight (kg) follow-up: 26 weeks	1¢	RCT	Serious	Not serious	Serious ^h	Serious	-	54	63	MD 0.6 [0.0 to 1.2]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.14
Weight loss interventions vs usual care assessed with: BMI (kg/m²) follow-up: range 5 weeks	2 ^b	RCT	Very serious ^g	Not serious	Serious ^h	Very serious ⁱ	-	40	20	MD 1.48 [-0.51 to 3.46]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.17
Weight loss interventions vs usual care assessed with: BMI (kg/m²) follow-up: 26 weeks	1¢	RCT	Serious ⁱ	Not serious	Serious ^h	Very serious ⁱ	-	94	83	MD 0.20 [-1.41 to 1.81]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.17
Psychological functioning and	wellbeir	ng – post-i	ntervention:									

Education and weight loss coaching (diet and exercise) vs usual care with: Depression anxiety stress scale (DASS) Depression Anxiety Stress Follow-up: 26 weeks	1°	RCT	Serious ⁱ	Not serious	Serious ^h	Very serious ⁱ	-	43	61	Depression MD 1.20 [-3.15 to 5.55] Anxiety MD 0.4 [-2.95 to 3.75] Stress MD 0.5 [-3.74 to 4.74]	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.18 to 1.20
Population subgroups 1, 2, 3, 4, 5 and 6 - not reported (no subgroup analysis was performed)												
Psychological functioning and wellbeing – long-term follow-up: no studies were identified that reported for this outcome												
-	-	-	-	-	-	-	-	-	-	-	-	-
Social participation – post-intervention or long-term follow-up: no studies were identified that reported for this outcome												
-	-	-	-	-	-	-	-	-	-	-	-	-
Self-efficacy – post-intervention or long-term follow-up: no studies were identified that reported for this outcome												
-	-	-	-	-	-	-	-	-	-	-	-	-
Change in use of medications – post-intervention												
Education and weight loss coaching (diet and exercise) vs usual care assessed with: Frequency n/N Follow-up: 26 weeks	1°	RCT	Serious ^ı	Not serious	Serious ^h	Very serious ⁱ	-	27/38	45/56	RR 0.88 (0.7 to 1.12)	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.21
Population subgroups 1, 2, 3, 4, 5 and 6 - not reported (no subgroup analysis was performed)												
Change in use of medications – long-term follow-up: no studies were identified that reported for this outcome												
-	-	-	-	-	-	-	-	-	-	-	-	-
Falls – post-intervention or long-term follow-up: no studies were identified that reported for this outcome												

•	-	-	-	-	-	-	-	-	-	-	-	-
Adverse events – post-intervention:												
Education and weight loss coaching (diet and exercise) vs usual care assessed with: Frequency n/N Follow-up: range 26 weeks	1¢	RCT	Serious ⁱ	Not serious	Serious ^h	Serious ^j	-	32/79	45/80	RR 0.72 (0.52 to 1.00)	⊕⊖⊖ ⊖ Very low	Appendix 5 Analysis 1.22
Population subgroups 1, 2, 3, 4, 5 and 6 - not reported (no subgroup analysis was performed)												
Adverse events – long-term follow-up: no studies were identified that reported for this outcome												
•	-	-	-	-	-	-	-	-	-	-	-	-

Explanation

- a. Safari 2020, 30 day Low calorie prescribed diet intervention (1200kcal/day) plus 200mg celecoxib per day vs 200mg celecoxib/day only.
- b. Torlak 2022 contributes as 2 studies in the analyses as it had two weight loss intervention arms and one shared comparator group. Weight intervention consisted of a 5 week 5:2 intermittent diet consisting of two days consuming 600-700kcal/day and 5 days 1500-1700kcal per day Mediterranean diet with or without physiotherapy care (TENS and hotpack) compared to physiotherapy care only.
- c. Williams 2018 One face to face pain and lifestyle education session plus 6-month telephone weight loss health coaching for diet and physical activity compared to usual care.
- d. Risk of Bias: Downgrade one level for overall risk of bias in two studies (>25% of participants)
- e. Inconsistency: Downgrade two levels for high, unexplained heterogeneity > 75%
- f. Imprecision: Downgrade one level CIs and point estimates show appreciable benefit and harm; not downgraded two levels due to downgrade for inconsistency would have contributed to severity of imprecision.
- g. Risk of bias: Downgrade two levels for overall high risk of bias in most studies (>50% of participants)
- h. Indirectness: Single study
- i. Imprecision: Downgrade two levels CIs show appreciable benefit and harm and small numbers of participants
- j. Imprecision: Downgrade one level for small number of participants fewer than 400.
- k. Inconsistency: Downgrade one level for inconsistency, heterogeneity > 50%
- 1. Risk of bias: Downgrade one level risk of bias due to loss to follow-up for that outcome.